Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Draximage takes skeletal imaging agent to the US:

This article was originally published in Clinica

Executive Summary

Draximage has launched in the US a new formulation of a skeletal imaging agent for pinpointing areas of altered osteogenesis or bone growth. MDP-25 (99mTc-methylene diphosphonic acid kit), when used with gamma camera imaging, allows doctors to detect areas of abnormal osteogenesis, which show altered uptake, making it possible to visualise a variety of bone lesions. It is used in the assessment of metastatic bone disease, Paget's disease, arthritic disease and osteomyelitis. The new formulation produces more effective images of the extremities of the skeleton, particularly hands and feet, claims the company, a subsidiary of Mississauga, Ontario-based Draxis Health.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT058820

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel